Novo Nordisk promotes new GLP-1 receptor agonist to fight diabetes, obesity < Pharma < Article - KBR
Another Weight-Loss Trial Win for Weekly GLP-1 Drug | MedPage Today
Novo's fast-launching Ozempic puts Lilly on notice—and its GLP-1 pill is on its way | Fierce Pharma
Long-acting GLP-1 analogue #1
Novo Nordisk's insulin pen receives EU approval to treat type 2 diabetes
Type 2 Diabetes and the Role of GLP-1 | Diabetes Education for Patients | novoMEDLINK™
Novo Nordisk comments on role of off-label use in Ozempic shortfall
The 411 on a GLP-1
Liraglutide seems effective in obesity, says FDA reviewer - PMLiVE
Good News About GLP-1 Drugs and Cardiovascular Health - Type 2 Nation
FDA approves Novo Nordisk's semaglutide for weight management - Drug Discovery and Development
GLP-1 franchise powers progress at Novo Nordisk in 2021
The Now Generation & New Generation of GLP-1 RAs: Reshaping the Care of T2DM
Looking for Ozempic? Doctors are prescribing these diabetic alternatives for now | Connecticut Public
Novo Nordisk Stock: Growing Obesity Epidemic Will Generate Demand (NYSE:NVO) | Seeking Alpha
First Oral GLP-1 Receptor Agonist Approved for Type 2 Diabetes - MPR
GLP-1 receptor agonist for chronic weight management - Clinical Advisor
